Single dose oral aspirin for acute postoperative pain in adults

Derry, Sheena; Moore, R Andrew

doi:10.1002/14651858.cd002067.pub2

Cited by 24 publications

(15 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different effective plasma concentrations of CBD may be required for achieving different endpoints across clinical populations, which is a recognised trait in a number of other drugs and diseases. For example, aspirin (acetylsalicylic acid) is used at low doses for antiplatelet therapy, and at higher doses as an analgesic agent . With CBD, lower doses may be effective in anxiety relief, while higher doses may be required for effective reduction in epileptic seizures.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of cannabidiol dosing in clinical populations

Millar

Stone

Bellman

et al. 2019

Brit J Clinical Pharma

173

148

View full text Add to dashboard Cite

Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in a wide‐variety of contexts; however, its effective dose in different disease states remains unclear. This review aimed to investigate what doses have been applied in clinical populations, in order to understand the active range of CBD in a variety of medical contexts. Methods Publications involving administration of CBD alone were collected by searching PubMed, EMBASE and ClinicalTrials.gov . Results A total of 1038 articles were retrieved, of which 35 studies met inclusion criteria covering 13 medical contexts. Twenty‐three studies reported a significant improvement in primary outcomes (e.g. psychotic symptoms, anxiety, seizures), with doses ranging between <1 and 50 mg/kg/d. Plasma concentrations were not provided in any publication. CBD was reported as well tolerated and epilepsy was the most frequently studied medical condition, with all 11 studies demonstrating positive effects of CBD on reducing seizure frequency or severity (average 15 mg/kg/d within randomised controlled trials). There was no signal of positive activity of CBD in small randomised controlled trials (range n = 6–62) assessing diabetes, Crohn's disease, ocular hypertension, fatty liver disease or chronic pain. However, low doses (average 2.4 mg/kg/d) were used in these studies. Conclusion This review highlights that CBD has a potential wide range of activity in several pathologies. Pharmacokinetic studies as well as conclusive phase III trials to elucidate effective plasma concentrations within medical contexts are severely lacking and highly encouraged.

show abstract

Section: Discussionmentioning

confidence: 99%

“…For example, aspirin (acetylsalicylic acid) is used at low doses for antiplatelet therapy, and at higher doses as an analgesic agent. 44,45 With CBD, lower doses may be effective in anxiety relief, while higher doses may be required for effective reduction in epileptic seizures. In studies where there are good rationales for CBD use (e.g.…”

Section: Discussionmentioning

confidence: 99%

A systematic review of cannabidiol dosing in clinical populations

Millar

Stone

Bellman

et al. 2019

Brit J Clinical Pharma

173

148

View full text Add to dashboard Cite

show abstract

“…While there may be other components in some non-prescription analgesics, these are usually present infrequently, and at doses too low to have any major impact. An exception is caffeine, which adds to analgesic effects in acute pain, in conjunction with conventional analgesics, and at caffeine doses of 100 mg or above (Derry 2012). …”

Section: How the Intervention Might Workmentioning

confidence: 99%

Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews

Moore¹,

Wiffen

Derry³

et al. 2015

Cochrane Database of Systematic Reviews

Self Cite

View full text Add to dashboard Cite

There is a body of reliable evidence about the efficacy of some of the most commonly available drugs and doses widely available without prescription. The postoperative pain model is predominantly pain after third molar extraction, which is used as the industry model for everyday pain. The proportion of people with acute pain who get good pain relief with any of them ranges from around 70% at best to less than 20% at worst; low doses of some drugs in fast acting formulations were among the best. Adverse events were generally no different from placebo. Consumers can make an informed choice based on this knowledge, together with availability and price. Headache and migraine were not included in this overview.

show abstract

“…Aspirin (ASP) is a well-established non-steroidal anti-inflammatory drug (NSAID), with chemical stability and an inexpensive price. In addition to its long-term application as an antipyretic and analgesic for postoperative pain relief [21], ASP is also reported to substantially improve immunomodulatory function, manifested as regulatory T cells upregulation and Th17 cells downregulation in vitro [22]. In addition, systemic use of ASP revealed enhanced bone regeneration in vivo [23].…”

Section: Introductionmentioning

confidence: 99%

Icariin/Aspirin Composite Coating on TiO2 Nanotubes Surface Induce Immunomodulatory Effect of Macrophage and Improve Osteoblast Activity

You

Chen

et al. 2020

Coatings

View full text Add to dashboard Cite

Surface coating modification of titanium-based alloys is an efficient way to accelerate early osseointegration in dental implant fields. Icariin (ICA) is a traditional Chinese medicine that has bone activating functions, while aspirin (ASP) is a classical non-steroidal anti-inflammatory drug with good antipyretic and analgesic capabilities. Moreover, poly(lactic–co–glycolic acid) (PLGA) has attracted great attention due to its excellent biocompatibility and biodegradability. We superimposed an ASP/PLGA coating onto ICA loaded TiO2 nanotubes structure so as to establish an icariin/aspirin composite coating on TiO2 nanotubes surface. Scanning electron microscopy, X-ray photoelectron spectroscopy, a contact angle test and a drug release test confirmed the successful preparation of the NT–ICA–ASP/PLGA substrate, with a sustained release pattern of both ICA and ASP. Compared to those cultured on the Ti surface, macrophage cells on the NT-ICA-ASP/PLGA substrate displayed decreased M1 proinflammatory and enhanced M2 proregenerative genes and proteins expression, which implied activated immunomodulatory effect. Moreover, when cultured with conditioned medium from macrophages, osteoblast cells on the NT-ICA-ASP/PLGA substrate revealed improved cell proliferation, adhesion and osteogenic genes and proteins expression, compared with those on the Ti surface. The abovementioned results suggest that the established NT-ICA-ASP/PLGA substrate is a promising candidate for functionalized coating material in Ti implant surface modification.

show abstract

Single dose oral aspirin for acute postoperative pain in adults

Cited by 24 publications

References 134 publications

A systematic review of cannabidiol dosing in clinical populations

A systematic review of cannabidiol dosing in clinical populations

Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews

Icariin/Aspirin Composite Coating on TiO2 Nanotubes Surface Induce Immunomodulatory Effect of Macrophage and Improve Osteoblast Activity

Contact Info

Product

Resources

About